Abstracts tagged "Biomarkers"

Abstract Number: 1985 • 2016 ACR/ARHP Annual Meeting
IL-18 Elevation in Macrophage Activation Syndrome: Human Evidence for a Chronic Set-Point and Murine Evidence for a Non-Hematopoietic Source
Zeshan Tariq¹, Eric Weiss², Wendy Goodspeed³, Raphaela Goldbach-Mansky⁴ and Scott Canna², ¹Autoinflammatory Pathogenesis Unit, NIAMS/NIH, Bethesd, MD, ²Autoinflammatory Pathogenesis Unit, NIAMS/NIH, Bethesda, MD, ³Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁴Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Macrophage Activation Syndrome (MAS) is a life-threatening sepsis-like condition complicating many systemic JIA (sJIA) and Adult-Onset Stills Disease (AOSD) patients. We recently identified that…
Abstract Number: 2520 • 2016 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab
Cecilie Heegaard Brahe¹, Mikkel Østergaard², Julia Sidenius Johansen³, Nadine A. Defranoux⁴, Ching Chang Hwang⁵, Xingbin Wang⁴, Rebecca J. Bolce⁴, Eric H. Sasso⁴, Kim Hørslev-Petersen⁶, Kristian Stengaard-Pedersen⁷, Lykke Midtbøll Ørnbjerg⁸, Peter Junker⁹, Torkell Ellingsen¹⁰, Palle Ahlquist¹¹, Hanne Lindegaard¹², Asta Linauskas¹³, Annette Schlemmer¹⁴, Mette Yde Dam¹⁵, Ib Tønder Hansen¹⁶, Tine Lottenburger¹¹, Christian G. Ammitzbøll¹⁷, Anette Jørgensen¹⁷, Sophine B. Krintel⁸, Johnny Lillelund Raun¹⁸ and Merete Lund Hetland^3,19, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ³Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁴Crescendo Bioscience Inc., South San Francisco, CA, ⁵Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁶King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁷Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁹Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ¹⁰Department of Rheumatology, Odense University Hospital, Odense, DK, Odense, Denmark, ¹¹Department of Medicine, Vejle Regional Hospital, Vejle, Denmark, ¹²The DANBIO registry and the Danish Departments of Rheumatology, Odense, Denmark, ¹³The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ¹⁴9Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁵Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Rheumatology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark, ¹⁸King Christian X Hospital for Rheumatic Diseases, South Jutland Hospital, Graasten, Denmark, ¹⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark,, Copenhagen, Denmark
Background/Purpose: The multi-biomarker disease activity (MBDA) score, which combines 12 serum biomarkers to measure RA disease activity on a scale of 1−100, has been found…
Abstract Number: 2871 • 2016 ACR/ARHP Annual Meeting
Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Teresa Aberle¹, Virginia C. Roberts¹, Joel M. Guthridge³, Diane L. Kamen⁴, Gary S. Gilkeson⁵, Michael Weisman⁶, Mariko Ishimori⁶, Daniel J Wallace⁷, David Karp⁸, Kathy L. Sivils¹, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁰Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Childrens Hospital, Cincinnati, OH, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. Blood relatives (Rel) of lupus patients…
Abstract Number: 72 • 2016 ACR/ARHP Annual Meeting
Longitudinal Expression of CXCL10 in Psoriasis Patients That Develop Psoriatic Arthritis
Fatima Abji¹, Remy Pollock², Kun Liang³, Vinod Chandran⁴ and Dafna D Gladman⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Longitudinal Expression of CXCL10 in Psoriasis Patients that Develop Psoriatic Arthritis Patients Fatima Abji1, Remy Pollock1 Kun Liang2, Vinod Chandran1,3, Dafna D. Gladman1,3 1University of…
Abstract Number: 786 • 2016 ACR/ARHP Annual Meeting
Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
Alfred Kim¹, Deepali Sen², Vibeke Strand³, Qiang John Fu⁴, Nancy Mathis¹, Robin Bruchas⁵, Nick Staten⁵, Martin Schmidt⁶, Paul Olson⁵, Chad Stiening⁵ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³Stanford University School of Medicine, Palo Alto, CA, ⁴Biostatistics, Saint Louis University, Saint Louis, MO, ⁵Kypha, Inc., Saint Louis, MO, ⁶Kypha, Inc., St. Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 1304 • 2016 ACR/ARHP Annual Meeting
2D and 3D Measurements of Osteoarthritis Joint Space Width Have Good Agreement in Radiographically Normal Knees but Poor Agreement with Advancing Kellgren-Lawrence Grade: Data from the Osteoarthritis Initiative
Aaron Ray¹, Michael A Bowes², Bright Dube¹, Elizabeth M.A. Hensor¹, Andrew J Barr¹ and Philip G. Conaghan¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Imorphics Ltd, Manchester, United Kingdom
2D and 3D Measurements of Osteoarthritis Joint Space Width have Good Agreement in Radiographically Normal Knees but Poor Agreement with Advancing Kellgren-Lawrence Grade: Data from…
Abstract Number: 1997 • 2016 ACR/ARHP Annual Meeting
Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis – Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
Bente Glintborg¹, Tina Marie Kringelbach¹, Estrid Høgdall¹, Inge Juul Sørensen², Dorte Vendelbo Jensen², Anne Gitte Loft³, Oliver Hendricks⁴, Inger Marie Jensen Hansen², Asta Linauskas², Salome Kristensen², Hanne Lindegaard⁵, Henrik Nordin², Nils Bolstad⁶, David Warren⁶, Johanna Gehin⁶, Guro Løvik Goll⁶, Kathrine Lederballe Grøn², Grith Eng², Christian Enevold¹, Claus Henrik Nielsen¹, Julia Sidenius Johansen¹ and Merete Lund Hetland¹, ¹Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ²The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ³Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁴Dep. of Rheumatology, King Christians Hospital for Rheumatic Diseases, Copenhagen, Denmark, ⁵The DANBIO registry and the Danish Departments of Rheumatology, Odense, Denmark, ⁶Department of Medical Biochemistry, OUS-Radiumhospitalet and Diakonhjemmet Sykehus, Oslo, Norway
Background/Purpose: According to national guidelines issued in 2015, a non-medical switch from originator infliximab (IFX) (Remicade) to biosimilar Remsima was conducted in all Danish patients…
Abstract Number: 2521 • 2016 ACR/ARHP Annual Meeting
Lower Baseline 14-3-3η Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients
Shintaro Hirata¹, Anthony Marotta², Kentaro Hanami¹ and Yoshiya Tanaka³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Serum 14-3-3η is a mechanistic marker that is involved in the pathogenesis of RA and is a potent up-regulator of IL-6. We previously reported…
Abstract Number: 2892 • 2016 ACR/ARHP Annual Meeting
Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low
Tamao Nakashita¹, Shinji Motojima², Akira Jibatake², Akira Yoshida² and Yoshiki Yamamoto², ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: KL-6 is a glycoprotein expressed on and released from type 2 alveolar cells and the measurement of KL-6 in serum was developed by Kohno…
Abstract Number: 292 • 2015 ACR/ARHP Annual Meeting
Neoepitope Biomarkers As Biomarkers of Polymyositis and Dermatomyositis and Functional Status
Anders Nedergaard¹, Kim Henriksen², Morten Asser Karsdal³, Wendy White⁴ and Xiang Guo⁴, ¹Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, Copenhagen NW, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Polymyositis (PM) and Dermatomyositis (DM) are inflammatory conditions characterized by persistent inflammation of muscle tissue (and for DM also skin). Myositis has been shown…
Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Jose Inciarte-Mundo¹, Julio Ramírez¹, Virginia Ruiz-Esquide¹, M. Victoria Hernández¹, Oscar Camacho¹, Sonia Cabrera-Villalba¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ²Immunology Department, Hospital Clinic i Provincial, Barcelona, Spain
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…
Abstract Number: 1105 • 2015 ACR/ARHP Annual Meeting
The IgG/IgG4 mRNA Ratio By Quantitative PCR Accurately Diagnoses IgG4-Related Disease and Predicts Treatment Response
Lowiek Hubers¹, Marieke Doorenspleet², Paulus Klarenbeek³, Emma Culver⁴, Lucas Maillette de Buy Wenniger⁵, Roger Chapman⁴, Stan Van de Graaf⁶, Joanne Verheij⁷, Thomas Van Gulik⁸, Frank Baas⁹, Ellie Barnes⁴, Ulrich Beuers¹ and Niek De Vries³, ¹Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Translational Gastroenterology Unit and NDM Oxford University, Translational Gastroenterology Unit and NDM Oxford University, John Radcliffe Hospital/Oxford University, Oxford, United Kingdom, ⁵1Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research,, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Dept. of Pathology, Dept. of Pathology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁸Dept. of Surgery, Dept. of Surgery, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁹Dept. of Genome Analysis, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose : IgG4-associated cholangitis (IAC) and autoimmune pancreatitis (AIP) are major manifestations of IgG4-related disease (IRD). Misdiagnosis and inadequate treatment are common since IAC and…
Abstract Number: 1667 • 2015 ACR/ARHP Annual Meeting
Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Canestri, Clara Di Mario, Marcin Nowik and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for Rheumatoid Arthritis (RA) and it is a modifier of B cell subsets in vivo, inducing changes in…
Abstract Number: 2019 • 2015 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammatory Arthritis in First Degree Relatives of Patients with Rheumatoid Arthritis and Their Association with Lifestyle Risk Factors
Jamie C Sergeant and RA-MAP Consortium, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP) and C-reactive protein (CRP) are known serum biomarkers of inflammatory arthritis (IA) and have potential predictive…
Abstract Number: 2612 • 2015 ACR/ARHP Annual Meeting
Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: A number of composite outcome measures have been validated to quantify disease activity in Rheumatoid Arthritis (RA). Few studies have been published on the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].